Iksung Cho has been named vice president of Biostatistics at Novavax, Inc. Mr. Cho joined the company in December 2015 as executive director, Biostatistics responsible for coordinating statistical and statistical programming activities for vaccine candidates in various stages of clinical development.

Previously, he was senior statistician at PATH, an international nonprofit organization that aims to accelerate innovation across vaccines, drugs, diagnostics, devices and system and service innovations. Mr. Cho also held positions of increasing responsibility in biostatistics and data management at Aviron, Merck and MedImmune, where he was vice president of Global Biostatistics. 
 
“Iksung has rapidly become a critical part of our team,” said Gregory M. Glenn, M.D., president of R&D at Novavax. “We expect to leverage his deep experience in biostatistics to evaluate important data readouts from the pivotal Phase III Resolve trial of our RSV F Vaccine in older adults and the Phase II rollover trial in older adults later this year.”